Advancing new treatments to help people lead vital lives.

Aytu BioPharma is committed to studying new treatments to make people’s lives better. We are constantly searching to uncover and develop new treatments with real potential. Research and development are critical to the lives of the patients we serve. Aytu is focused on better outcomes for better living.

Current Pipeline

AR101 (enzastaurin)

AR101 (enzastaurin) is a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (VEDS)